Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie’s elagolix shows benefits in new uterine fibroids study

AbbVie’s elagolix shows benefits in new uterine fibroids study

14th March 2018

AbbVie has announced new clinical trial data demonstrating the benefits of its investigational drug elagolix in the treatment of women with uterine fibroids.

Conducted in collaboration with Neurocrine Biosciences, the phase III ELARIS UF-II study showed that elagolix, when used in combination with low-dose hormone therapy, had a significant effect on reducing heavy menstrual bleeding.

It was shown that 76.2 percent of women with uterine fibroids achieved clinical response, compared to 10.1 percent of those receiving a placebo. It means that the drug was able to meet all of its primary and secondary endpoints in the trial.

This is the second of two pivotal phase III trials assessing elagolix in this indication, with the findings of ELARIS UF-II shown to be consistent with the results from the earlier ELARIS UF-I study.

Dr Dawn Carlson, vice-president for general medicine development at AbbVie, said: "Millions of women currently diagnosed with uterine fibroids are faced with limited non-surgical options. The results from this study demonstrate elagolix has the potential to be an important oral treatment option for women suffering from uterine fibroids."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.